Myomo outlines 10% revenue growth target for 2026 while expanding recurring patient sources and international operations (NYSE:MYO)

Myomo (MYO) Q4 2025 earnings call recap: revenue growth, record orders, Elevance payer deal, 2026 guidance, margins, risks & strategy—read now.

You will be redirected in 10 seconds.